荷兰药物监管科学的演进:不止于国别报告
本文综述荷兰药物监管科学的发展历程,梳理三个关键阶段:TI Pharma Escher项目、荷兰药品评价委员会作为催化剂的跃升、以及荷兰监管科学网络与多方参与。研究议程受欧盟孤儿药立法(2001年)和药物警戒立法(2012年)等法律框架动态演变的影响,临床药理学学科对监管科学形成贡献显著,多方连接监管科学活动至关重要。
要点
- 荷兰药物监管科学经历了三个关键发展阶段,形成活跃的全国性及国际化社区。
- 欧盟孤儿药立法(2001年)和药物警戒立法(2012年)等法律框架演变影响了研究议程。
- 临床药理学对监管科学影响显著,参与讨论新药上市批准所需临床证据水平。
核心结论
- 荷兰药物监管科学通过多方协作和关键事件推动,已嵌入药物研究、临床药理学、政策制定与监管的生态系统中。
- 连接学术界、欧洲药品管理局、国家机构、患者组织和EFPIA等多方的监管科学活动是关键。
研究设计与样本
- 本文为综述,梳理荷兰药物监管科学的发展历程与协作因素。
主要发现
- 识别出三个关键阶段:TI Pharma Escher项目、荷兰药品评价委员会作为大跃升的催化剂、荷兰监管科学网络与多方参与。
- 研究议程受欧盟孤儿药立法(2001年)和欧盟药物警戒立法(2012年)等法律框架动态演变的影响。
- 临床药理学学科对监管科学形成影响显著,贡献于新药上市批准所需临床证据水平的讨论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In the Netherlands, drug regulatory science is a vibrant national and internationally oriented community. In this review, we present the factors that have contributed to this successful collaboration between relevant stakeholders and that led to a surge of activities around how regulatory science became embedded in the ecosystem of medicines research, clinical pharmacology, policymaking and regulation. We distinguished three pivotal episodes: (i) TI Pharma Escher-project, (ii) Dutch Medicines Evaluation Board as catalyst of the big jump, and (iii) Regulatory Science Network Netherlands and multistakeholder engagement. The research agenda has been influenced by the dynamic evolution of legal frameworks in Europe, such as the EU orphan medicines legislation of 2001 and the EU pharmacovigilance legislation of 2012. All these developments have inspired and have raised pertinent regulatory sciences questions. Furthermore, clinical pharmacology as a discipline has been very influential in shaping regulatory science, contributing to discussions on the level of clinical evidence that is necessary to justify marketing approval of a new medicine. With a growing interest of multiple parties such as academics, European Medicines Agency, national agencies, patient organizations and EFPIA, connecting regulatory science activities is key.
引用
- Pasmooij AMG, Mol PGM, Bot JC, et al. The Evolution of Drug Regulatory Sciences in the Netherlands: More than a Country Report. Clin Pharmacol Ther. 2024. PMID: 38679943. doi:10.1002/cpt.3275
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。